The iconic rise of Viagra has consistently remained a example of pharmaceutical success, but its legacy within the broader industry now triggers questions about potential gains. Alternative versions are eroding market knockoff share, prompting worries that investing in companies significantly dependent to Viagra's once-dominant influence could be a